Although the pathogenesis of DCM is not completely understood, the vital role of overactivated renin-angiotensin system (RAS) in the development and progression of DCM has been widely recognized and administration of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have substantially improved the clinical outcomes of patients with DCM (McDonagh and Metra, 2021). The gene discussed is REN; the disease is familial dilated cardiomyopathy.